Penile squamous cell carcinoma · line 1 · TIP (paclitaxel + ifosfamide + cisplatin, penile SCC)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-TIP-PENILE |
| ID | IND-PENILE-SCC-METASTATIC-1L-TIP |
|---|---|
| Type | Indication |
| Status | reviewed 2026-07-11 | pending_clinical_signoff |
| Diseases | DIS-PENILE-SCC |
| Sources | SRC-EAU-PENILE-2024 |
Notes
STUB — Phase 1. Transcribed from DIS-PENILE-SCC narrative ("TIP (paclitaxel + ifosfamide + cisplatin) per EAU"). REG-TIP-PENILE dosing drafted per the general TIP-triplet convention (paclitaxel d1; ifosfamide+cisplatin d1-3 with mandatory mesna; q21d), distinct from the germ-cell-tumor-salvage TIP schedule already in this KB (REG-TIP-GCT-SALVAGE). Requires medical-oncology co-lead signoff before clinical publication (CHARTER §6.1; dev-mode-exempted for draft merge).
Used By
Algorithms
ALGO-PENILE-SCC-1L- ALGO-PENILE-SCC-1L
Indication
IND-PENILE-SCC-METASTATIC-1L-CISPLATIN-5FU- IND-PENILE-SCC-METASTATIC-1L-CISPLATIN-5FU